SALES AS OF 30 SEPTEMBER 2015: +4.8 % growth

Continued growth in health activities: +8.2 %

Longjumeau, 3 November 2015

PCAS (Euronext Paris: PCA), a specialist in developing and producing complex molecules for life sciences and innovative technologies, has announced the publication of its consolidated net sales as of 30 September 2015.

At September 30, 2015, consolidated net sales for the PCAS Group are up 4.8 %, at €123.5 million compared to the same period for the previous year.

In €M 9 months 2015 9 months 2014 % change
Net sales 123.5 117.9 +4.8 %
Pharmaceutical synthesis 80.1 74.0 +8.2 %
Fine specialty chemicals 43.5 43.9 -1.0 %

Pharmaceutical synthesis (65 % of consolidated net sales)

The pharmaceutical synthesis activity amounted to €80.1 million, up 8.2 % on the first nine months of 2014, confirming the performance of our teams and the relevance of our positioning in all the geographical zones. The activity has been supported by the result of commercial efforts:

  • Active substances developed in partnership with leading laboratories and biotech companies.
     
  • Proprietary molecules: active ingredients for generics in particular.

Fine specialties chemicals (35 % of consolidated net sales)

Net sales of fine specialties chemicals amounted to €43.5 million, down 1.0 % on the first nine months of 2014. Two opposing trends can be observed in this segment:

  • The strong progress of performance fine chemicals and new technologies, with gains in market shares in Germany and Asia.
     
  • The decline in the perfumery products-flavors-cosmetics activities which is under strategic review.

Outlook for the current year

On the basis of the first nine months of the year and available trade information, the company confirms its target of growth in net sales for the whole of 2015 in excess of the growth achieved in the first half of the year.

  NEXT FINANCIAL DISCLOSURE:
2015 sales, February 2, 2016

ABOUT PCAS
PCAS specialises in the development and production of complex molecules for Life Sciences and Innovative Technologies. With 7% of its turnover dedicated to R&D and a wide international presence, PCAS is the preferred industrial partner of market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments, and also includes two subsidiaries with very strong potential: Protéus in biotechnology and Enersens in high-performance insulation. With a particularly high standard of performance, PCAS achieved net sales of €166 million in 2014 and employs nearly 900 people in six countries.

For more information about PCAS: www.pcas.com:
http://www.pcas.com/

PCAS NewCap
Vincent Touraille / Eric Moissenot
PCAS		 Emmanuel Huynh / Louis-Victor Delouvrier
NewCap
Financial Communication & investors relations
Tél. : +33 1 69 79 61 32
www.pcas.com

 		 Tél. : +33 1 44 71 98 53
pcas@newcap.eu
PR_pcas_revenue_9_months_2015:
http://hugin.info/143512/R/1963857/716679.pdf


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: PCAS via Globenewswire
HUG#1963857